Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Fractyl Health received authorization to start a Phase 1/2 clinical trial of RJVA-001, its first gene therapy candidate aimed at treating type 2 diabetes by enabling nutrient-responsive GLP-1 expression in the pancreas. This marks the company's advancement to a dual clinical-stage biotech, with RJVA-001 being the first adeno-associated virus-based …